SGLT2 Inhibition in Heart Failure with a Preserved Ejection Fraction — A Win against a Formidable Foe
Mark H. Drazner
Abstract
Mark Drazner comments on the findings of the EMPEROR-Preserved trial, which assessed the potential benefit of empagliflozin in patients with a preserved EF. He notes that the findings represent a major win against a medical condition that had previously proved formidable.
Topics & Concepts
EmpagliflozinMedicineEjection fractionHeart failureCardiologyEmperorInternal medicineAncient historyEndocrinologyDiabetes mellitusHistoryType 2 Diabetes MellitusDiabetes Treatment and ManagementPancreatic function and diabetesMetabolism, Diabetes, and Cancer